| Date:                   | _2022/5/25            |  |
|-------------------------|-----------------------|--|
| Your Name:              | Dan Wu                |  |
| Manuscript Title:       | <b>Bioinformatics</b> | analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in car | ncers                 |  |
| Manuscript number (i    | f known):             |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   | l.                            | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| lectures, presentations, |  | XNone  |  |
|--------------------------|--|--------|--|
|                          | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6                        | Payment for expert testimony                                     | XNone  |  |
| 7                        | Support for attending meetings and/or travel                     | XNone  |  |
|                          |  |        |  |
| 8                        | Patents planned, issued or pending                               | XNone  |  |
| 9                        | Participation on a Data  | X None |  |
| 5                        | Safety Monitoring Board or                                       |        |  |
|                          | Advisory Board   |        |  |
| 10                       | Leadership or fiduciary role                                     | XNone  |  |
|                          | in other board, society,   |        |  |
|                          | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11                       | Stock or stock options   | XNone  |  |
|                          |  |        |  |
|                          |  |        |  |
| 12                       | 12 Receipt of equipment,   | XNone  |  |
|                          | materials, drugs, medical<br>writing, gifts or other             |        |  |
|                          | services   |        |  |
| 13                       | Other financial or non-  | XNone  |  |
|                          | financial interests  |        |  |
|                          |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:                  | _2022/5/25  |
|------------------------|---|
| Your Name:             | Chuan Jiang   |
| Manuscript Title:      | Bioinformatics analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in ca | ncers   |
| Manuscript number (    | if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| lectures, presentations, |  | XNone  |  |
|--------------------------|--|--------|--|
|                          | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6                        | Payment for expert testimony                                     | XNone  |  |
| 7                        | Support for attending meetings and/or travel                     | XNone  |  |
|                          |  |        |  |
| 8                        | Patents planned, issued or pending                               | XNone  |  |
| 9                        | Participation on a Data  | X None |  |
| 5                        | Safety Monitoring Board or                                       |        |  |
|                          | Advisory Board   |        |  |
| 10                       | Leadership or fiduciary role                                     | XNone  |  |
|                          | in other board, society,   |        |  |
|                          | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11                       | Stock or stock options   | XNone  |  |
|                          |  |        |  |
|                          |  |        |  |
| 12                       | 12 Receipt of equipment,   | XNone  |  |
|                          | materials, drugs, medical<br>writing, gifts or other             |        |  |
|                          | services   |        |  |
| 13                       | Other financial or non-  | XNone  |  |
|                          | financial interests  |        |  |
|                          |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:                  | _2022/5/25  |
|------------------------|---|
| Your Name:             | Jing-Jing Zheng   |
| Manuscript Title:      | Bioinformatics analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in ca | ncers   |
| Manuscript number (    | if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| lectures, presentations, |  | XNone  |  |
|--------------------------|--|--------|--|
|                          | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6                        | Payment for expert testimony                                     | XNone  |  |
| 7                        | Support for attending meetings and/or travel                     | XNone  |  |
|                          |  |        |  |
| 8                        | Patents planned, issued or pending                               | XNone  |  |
| 9                        | Participation on a Data  | X None |  |
| 5                        | Safety Monitoring Board or                                       |        |  |
|                          | Advisory Board   |        |  |
| 10                       | Leadership or fiduciary role                                     | XNone  |  |
|                          | in other board, society,   |        |  |
|                          | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11                       | Stock or stock options   | XNone  |  |
|                          |  |        |  |
|                          |  |        |  |
| 12                       | 12 Receipt of equipment,   | XNone  |  |
|                          | materials, drugs, medical<br>writing, gifts or other             |        |  |
|                          | services   |        |  |
| 13                       | Other financial or non-  | XNone  |  |
|                          | financial interests  |        |  |
|                          |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:                  | _2022/5/25  |
|------------------------|---|
| Your Name:             | De-Sheng Luo  |
| Manuscript Title:      | Bioinformatics analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in ca | ncers   |
| Manuscript number (    | if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| lectures, presentations, |  | XNone  |  |
|--------------------------|--|--------|--|
|                          | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6                        | Payment for expert testimony                                     | XNone  |  |
| 7                        | Support for attending meetings and/or travel                     | XNone  |  |
|                          |  |        |  |
| 8                        | Patents planned, issued or pending                               | XNone  |  |
| 9                        | Participation on a Data  | X None |  |
| 5                        | Safety Monitoring Board or                                       |        |  |
|                          | Advisory Board   |        |  |
| 10                       | Leadership or fiduciary role                                     | XNone  |  |
|                          | in other board, society,   |        |  |
|                          | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11                       | Stock or stock options   | XNone  |  |
|                          |  |        |  |
|                          |  |        |  |
| 12                       | 12 Receipt of equipment,   | XNone  |  |
|                          | materials, drugs, medical<br>writing, gifts or other             |        |  |
|                          | services   |        |  |
| 13                       | Other financial or non-  | XNone  |  |
|                          | financial interests  |        |  |
|                          |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:                  | _2022/5/25     |  |
|------------------------|----------------|--|
| Your Name:             | Ji Ma          |  |
| Manuscript Title:      | Bioinformatics | analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in ca | ncers          |  |
| Manuscript number (    | if known):     |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for lectures, presentations,                | XNone  |  |
|----|--|--------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6  | Payment for expert testimony                                     | XNone  |  |
| 7  | Support for attending meetings and/or travel                     | XNone  |  |
|    |  |        |  |
| 8  | Patents planned, issued or pending                               | XNone  |  |
| 9  | Participation on a Data  | X None |  |
| 5  | Safety Monitoring Board or                                       |        |  |
|    | Advisory Board   |        |  |
| 10 | Leadership or fiduciary role                                     | XNone  |  |
|    | in other board, society,   |        |  |
|    | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11 | Stock or stock options   | XNone  |  |
|    |  |        |  |
|    |  |        |  |
| 12 | Receipt of equipment,  | XNone  |  |
|    | materials, drugs, medical<br>writing, gifts or other             |        |  |
|    | services   |        |  |
| 13 | Other financial or non-  | XNone  |  |
|    | financial interests  |        |  |
|    |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:                  | _2022/5/25  |
|------------------------|---|
| Your Name:             | Hai-Feng Que  |
| Manuscript Title:      | _ Bioinformatics analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in ca | ncers   |
| Manuscript number (    | if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for lectures, presentations,                | XNone  |  |
|----|--|--------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6  | Payment for expert testimony                                     | XNone  |  |
| 7  | Support for attending meetings and/or travel                     | XNone  |  |
|    |  |        |  |
| 8  | Patents planned, issued or pending                               | XNone  |  |
| 9  | Participation on a Data  | X None |  |
| 5  | Safety Monitoring Board or                                       |        |  |
|    | Advisory Board   |        |  |
| 10 | Leadership or fiduciary role                                     | XNone  |  |
|    | in other board, society,   |        |  |
|    | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11 | Stock or stock options   | XNone  |  |
|    |  |        |  |
|    |  |        |  |
| 12 | Receipt of equipment,  | XNone  |  |
|    | materials, drugs, medical<br>writing, gifts or other             |        |  |
|    | services   |        |  |
| 13 | Other financial or non-  | XNone  |  |
|    | financial interests  |        |  |
|    |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:                  | _2022/5/25     |  |
|------------------------|----------------|--|
| Your Name:             | Chao Li        |  |
| Manuscript Title:      | Bioinformatics | analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in ca | ncers          |  |
| Manuscript number (    | if known):     |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | X_None  |
|----|--|---|
| 6  | Payment for expert testimony   | XNone   |
| 7  | Support for attending meetings and/or travel   | XNone   |
| 8  | Patents planned, issued or pending   | XNone   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | X_None  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | X_None  |
| 11 | Stock or stock options   | XNone   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | XNone   |
| 13 | Other financial or non-<br>financial interests   | Smartquerier Gene   Technology (Shanghai)   Co., Ltd.   Image: Color of the state of t |

The author is from Smartquerier Gene Technology (Shanghai) Co., Ltd.

## Please place an "X" next to the following statement to indicate your agreement:

| Date:                  | _2022/5/25     |  |
|------------------------|----------------|--|
| Your Name:             | Chao Ma        |  |
| Manuscript Title:      | Bioinformatics | analysis of SoxF family genes reveals potential regulatory mechanism and |
| diagnostic value in ca | ncers          |  |
| Manuscript number (    | if known):     |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   | l.                            | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | X_None  |
|----|--|---|
| 6  | Payment for expert testimony   | XNone   |
| 7  | Support for attending meetings and/or travel   | XNone   |
| 8  | Patents planned, issued or pending   | XNone   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | X_None  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | X_None  |
| 11 | Stock or stock options   | XNone   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | XNone   |
| 13 | Other financial or non-<br>financial interests   | Smartquerier Gene   Technology (Shanghai)   Co., Ltd.   Image: Color of the state of t |

The author is from Smartquerier Gene Technology (Shanghai) Co., Ltd.

## Please place an "X" next to the following statement to indicate your agreement:

| Date:                       | _2022/5/25  |  |  |
|-----------------------------|---|--|--|
| Your Name:                  | Hui-Yong Wang   |  |  |
| Manuscript Title:           | Bioinformatics analysis of SoxF family genes reveals potential regulatory mechanism and |  |  |
| diagnostic value in cancers |   |  |  |
| Manuscript number (         | if known):  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                               | XNone  |   |
|   | manuscript (e.g., funding,                                |  |   |
|   | provision of study materials,                             |  |   |
|   | medical writing, article                                  |  |   |
|   | processing charges, etc.)<br>No time limit for this item. |  |   |
|   | No time limit for this item.                              |  |   |
|   |   |  |   |
|   |   |  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                  | XNone  |   |
|   | any entity (if not indicated                              |  |   |
|   | in item #1 above).  |  |   |
| 3 | Royalties or licenses                                     | XNone  |   |
|   |   |  |   |
|   |   |  |   |
| 4 | Consulting fees   | XNone  |   |
|   |   |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | XNone   |
|----|--|---|
| 6  | Payment for expert testimony   | XNone   |
| 7  | Support for attending meetings and/or travel   | XNone   |
| 8  | Patents planned, issued or pending   | XNone   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | X_None  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | X_None  |
| 11 | Stock or stock options   | XNone   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | XNone   |
| 13 | Other financial or non-<br>financial interests   | Smartquerier Gene<br>Technology (Shanghai)<br>Co., Ltd. |

The author is from Smartquerier Gene Technology (Shanghai) Co., Ltd.

## Please place an "X" next to the following statement to indicate your agreement:

| Date:                         | _2022/5/25     |  |  |
|-------------------------------|----------------|--|--|
| Your Name:                    | Wei-Wang       |  |  |
| Manuscript Title:             | Bioinformatics | analysis of SoxF family genes reveals potential regulatory mechanism and |  |
| diagnostic value in cancers   |                |  |  |
| Manuscript number (if known): |                |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   | Time frame: past 36 months    |  |   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | XNone   |
|----|--|---|
| 6  | Payment for expert testimony   | XNone   |
| 7  | Support for attending meetings and/or travel   | XNone   |
| 8  | Patents planned, issued or pending   | XNone   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | X_None  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | X_None  |
| 11 | Stock or stock options   | XNone   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | XNone   |
| 13 | Other financial or non-<br>financial interests   | Smartquerier Gene<br>Technology (Shanghai)<br>Co., Ltd. |

The author is from Smartquerier Gene Technology (Shanghai) Co., Ltd.

## Please place an "X" next to the following statement to indicate your agreement:

| Date:                         |   |  |  |
|-------------------------------|---|--|--|
| Your Name:                    | Hong-Tao Xu   |  |  |
| Manuscript Title:             | Bioinformatics analysis of SoxF family genes reveals potential regulatory mechanism and |  |  |
| diagnostic value in cancers   |   |  |  |
| Manuscript number (if known): |   |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   | Time frame: past 36 months    |  |   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| lectures, presentat | Payment or honoraria for lectures, presentations,                | XNone  |  |
|---------------------|--|--------|--|
|                     | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6                   | Payment for expert testimony                                     | XNone  |  |
| 7                   | Support for attending meetings and/or travel                     | XNone  |  |
|                     |  |        |  |
| 8                   | Patents planned, issued or pending                               | XNone  |  |
| 9                   | Participation on a Data  | X None |  |
| 5                   | Safety Monitoring Board or                                       |        |  |
|                     | Advisory Board   |        |  |
| 10                  | Leadership or fiduciary role                                     | XNone  |  |
|                     | in other board, society,   |        |  |
|                     | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11                  | Stock or stock options   | XNone  |  |
|                     |  |        |  |
|                     |  |        |  |
| 12                  | Receipt of equipment,  | XNone  |  |
|                     | materials, drugs, medical<br>writing, gifts or other             |        |  |
|                     | services   |        |  |
| 13                  | Other financial or non-  | XNone  |  |
|                     | financial interests  |        |  |
|                     |  |        |  |

None

# Please place an "X" next to the following statement to indicate your agreement: